SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-21-001720
Filing Date
2021-02-25
Accepted
2021-02-25 07:37:55
Documents
14
Period of Report
2021-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adap-20210225x8k.htm   iXBRL 8-K 35501
2 EX-99.1 adap-20210225xex99d1.htm EX-99.1 358476
3 GRAPHIC adap-20210225xex99d1001.jpg GRAPHIC 9131
  Complete submission text file 0001558370-21-001720.txt   550379

Data Files

Seq Description Document Type Size
4 EX-101.SCH adap-20210225.xsd EX-101.SCH 3220
5 EX-101.LAB adap-20210225_lab.xml EX-101.LAB 16118
6 EX-101.PRE adap-20210225_pre.xml EX-101.PRE 10937
7 EXTRACTED XBRL INSTANCE DOCUMENT adap-20210225x8k_htm.xml XML 4922
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 21676435
SIC: 2836 Biological Products, (No Diagnostic Substances)